NCT00756041View on ClinicalTrials.gov

Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy

PHASE2TerminatedINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Diabetic Neuropathies
Interventions
DRUG

TAK-128

TAK-128 100 mg tablet, orally, once daily for up to 1 year.

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT00756041 - Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy | Biotech Hunter | Biotech Hunter